News
Can BHRT – Bioidentical Hormone Therapy in Maryland – Treat Hormonal Imbalance
The human body is a perfect assembly consisting of many parts that work in perfect harmony. Each of them has its own responsibilities and performs its function. Hormones are like managers of that circuit, responsible for the proper functioning...
News
Bora Pharmaceuticals acquires biologics CDMO facility
Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., to focus on the development of bio-pharmaceuticals. Bora Biologics has investors Taishin Healthcare Limited Partnership and Dr. Allen Chao,...
News
Abzena announces appointment of Petra Dieterich as Scientific Lead
Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs) has announced the appointment of Dr. Petra Dieterich, DPhil, MBA, as scientific lead.
Reporting to Abzena’s chief technology officer Dr....
News
In Preserved Ejection Fraction Trial Farxiga Shows Depth
DELIVER is the world's largest study of heart failure with intact ejection fraction. The DELIVER phase 3 trial produced favourable findings for AstraZeneca. It showed that Farxiga (dapagliflozin) reduced the primary outcome of cardiovascular death or deteriorating heart failure...
IT & Data Management
Ashfield Engage acquires smart data organization PROPENSITY4
Ashfield Engage, part of UDG Healthcare has acquired PROPENSITY4 - a ‘smart data’ organization and leader in the healthcare insights and analytics arena.
PROPENSITY4 integrates internal and external data assets and applies the right methodologies to derive detailed insight using...
Drug Research
Citius Pharma selects global CRO, Biorasi to help expand phase 3 Mino-Lok trial to additional sites outside US
Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, announced that it has selected Biorasi, LLC (Biorasi), a global clinical research organization (CRO), to help expand the company's phase 3 Mino-Lok trial to additional sites outside the United States. If approved,...
News
Sanofi Drug Ingredients Startup Takes off After Two Years
It's a fact: EUROAPI debuted on the Euronext exchange two years and one pandemic after Sanofi announced plans to sell off its European pharma ingredients division. Even though the market as a whole was going down, shares of the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















